CJC-1295 + Ipamorelin: the pharmacokinetic rationale is solid, the long-term human safety data is not.
The combination of a growth-hormone-releasing hormone analog (CJC-1295) with a ghrelin-receptor agonist (Ipamorelin) is the most commonly co-prescribed peptide stack in clinical anti-aging and GH-optimization practice, and historically the most widely compounded peptide combination in 503A pharmacy settings. The pharmacokinetic rationale — two different receptor pathways producing a synergistic GH pulse — is mechanistically sound and grounded in basic endocrinology. The evidence that the combined stack produces superior long-term outcomes in healthy adults does not exist. This page separates those two realities clearly.
- CJC-1295 acts at the pituitary GHRH receptor (GHRH-R); Ipamorelin acts at the ghrelin receptor (GHS-R1a). These are two different receptor systems at two different levels of the GH-secretion cascade.
- Combining GHRH-R + GHS-R1a stimulation produces a GH pulse that is additive-to-synergistic — larger than either agent alone. This is established in basic pituitary pharmacology research (Müller et al., Giustina and Veldhuis reviews).
- The specific combination of CJC-1295 + Ipamorelin has not been studied in a dedicated, adequately powered RCT for body-composition, longevity, or functional outcomes in healthy adults. The pharmacokinetic logic is sound; the clinical outcome evidence for the combination specifically is absent.
- Historical sourcing context: this combination was widely available through 503A compounding pharmacies for physicians prescribing off-label for adult GH optimization. FDA guidance in 2023–2024 significantly reduced legal 503A compounding availability for both CJC-1295 and Ipamorelin. The combination remains available through research-chemical vendors under RUO framing.
- Ipamorelin's key advantage as the GHRP component: it does not stimulate cortisol or prolactin, giving a cleaner GH pulse than GHRP-6 or GHRP-2 would in the same pairing.
- Long-term safety in healthy adults: not studied for this combination in any published trial.
The GH-axis cascade: why two receptors are better than one
Growth hormone secretion from pituitary somatotrophs is regulated by two opposing hypothalamic inputs: GHRH (stimulating) and somatostatin (inhibiting). GH release is also modulated peripherally by ghrelin acting at GHS-R1a receptors on somatotrophs and hypothalamic neurons. Understanding these three nodes — GHRH-R, GHS-R1a, and somatostatin receptors — explains why stacking a GHRH analog with a GHRP makes pharmacological sense.
GHRH binding at GHRH-R drives two processes: GH gene transcription (increasing the pool of GH available for secretion) and GH exocytosis from secretory granules (releasing the GH). GHS-R1a binding by ghrelin or a GHRP amplifies the exocytotic response through a separate second-messenger cascade (IP3/Ca²⁺ vs cAMP). Critically, GHS-R1a agonism also suppresses somatostatin release from the hypothalamus, reducing the inhibitory brake on somatotrophs. This dual mechanism — direct amplification of somatotroph secretory response + reduction of somatostatin inhibition — is why GHRH + GHRP produces a larger pulse than GHRH alone. Müller et al. (Physiol Rev, 1999; PMID 10221987) and Giustina and Veldhuis (Endocr Rev, 1998; PMID 9861545) provide the foundational neuroendocrine control reviews.
The specific combination of CJC-1295 (as the GHRH-R agonist) and Ipamorelin (as the GHS-R1a agonist) brings together: (1) CJC-1295's extended half-life for sustained GHRH-R stimulation and (2) Ipamorelin's GHS-R1a selectivity — meaning minimal cortisol or prolactin cross-activation. In theory, this gives a large, sustained GH axis activation without the neuroendocrine noise of less-selective GHRPs.
The compounding pharmacy history
The CJC-1295 + Ipamorelin combination rose to prominence in the 2010s through 503A compounding pharmacies — pharmacies that compound medications for individual patients under a physician's prescription, exempt from FDA drug-approval requirements under Section 503A of the Federal Food, Drug, and Cosmetic Act. Physicians in the anti-aging, functional medicine, and hormone-optimization space began prescribing these two peptides together, typically as separately reconstituted solutions administered at the same injection site or as a combined lyophilized vial produced by the compounding pharmacy.
This clinical use pattern created a population of physician-supervised users that vendor marketing cites as evidence of "clinical use" — but supervised compounding-pharmacy use is not equivalent to controlled clinical trial data. Without pre-defined endpoints, randomization, control groups, or systematic adverse-event reporting, compounding-pharmacy use generates anecdote and case reports, not Phase II/III evidence.
The FDA's 2023–2024 guidance on peptide compounding significantly restricted the 503A availability of both CJC-1295 and Ipamorelin. Under FDA's list of bulk drug substances eligible for compounding under 503A, unapproved peptides face increasing scrutiny. As of April 2026, neither CJC-1295 nor Ipamorelin appears on the FDA's 503A positive list; their compounding availability is legally uncertain and varies by state-level pharmacy board interpretation. The combination remains available through research-chemical vendors, marketed under RUO framing.
What the evidence actually supports for this stack
What is supported:
- The mechanistic rationale (GHRH-R + GHS-R1a synergy) is established in basic pharmacology and is not in dispute.
- CJC-1295 alone (Teichman 2006, PMID 16352683) produces sustained GH/IGF-1 elevation in healthy adults with acceptable short-term tolerability.
- Ipamorelin alone (Raun 1998, PMID 9849822; Beck 2014 Phase II) is characterized as a selective GHS-R1a agonist with a clean safety profile in its Phase II development program.
- Short-acting GHRH + GHRP combinations have been studied in basic pituitary pharmacology work confirming synergistic GH release (though not specifically CJC-1295 DAC + Ipamorelin in a clinical RCT).
What is not supported by evidence:
- That the combination of CJC-1295 specifically + Ipamorelin specifically produces superior body-composition outcomes compared to either alone in healthy adults — this has not been tested in a published RCT.
- That the sustained GH/IGF-1 elevation from the combination (CJC-1295 DAC's prolonged half-life + regular Ipamorelin pulses) is safe at any specific dosing interval over months to years of use — no published trial has studied this.
- That this combination prevents aging, extends lifespan, improves longevity biomarkers, or produces any of the anti-aging outcomes marketed under this stack name — not demonstrated in any adequately powered human trial.
Pharmacokinetic interactions between the two compounds
CJC-1295 with DAC has a 6–8 day plasma half-life, producing sustained GHRH-R stimulation. Ipamorelin has a 2-hour SC half-life, producing pulsatile GHS-R1a stimulation timed to injection. The combination creates a background of sustained GHRH-R engagement (from CJC-1295) on which Ipamorelin's GH-releasing pulses are superimposed.
Ionescu and Frohman (JCEM, 2006; PMID 16954163) showed that natural pulsatile GH secretion persists even during continuous CJC-1295-driven GHRH-R stimulation — the somatotroph's normal pulsatility is not abolished. Adding Ipamorelin pulses to this background amplifies those already-augmented pulses further. Whether the magnitude of GH output from this combined pattern versus CJC-1295 alone produces additional physiological benefit or additional safety risk is not established.
| Parameter | CJC-1295 with DAC | Ipamorelin | Stack interaction |
|---|---|---|---|
| Target receptor | GHRH-R (pituitary somatotroph) | GHS-R1a (somatotroph + hypothalamus) | Two independent receptor systems — additive |
| Half-life | ~6–8 days | ~2 hr SC | Sustained background + pulsatile peaks |
| GH release profile | Sustained (bleed) with preserved pulsatility | Sharp pulse at injection | Amplified pulses on elevated baseline |
| Cortisol / prolactin | Minimal | Minimal | Minimal (advantage of Ipamorelin as GHRP partner) |
| Appetite stimulation | None (GHRH-R; no ghrelin mimicry) | Mild (partial ghrelin-like effect) | Mild appetite increase from Ipamorelin component |
| Insulin resistance risk | Moderate (sustained GH) | Low-moderate (pulsatile GH) | Moderate; individual monitoring warranted |
How dosing is typically structured in research protocols
Research dosing protocols for this combination — derived from 503A compounding pharmacy prescribing patterns, not from published clinical RCTs — typically use:
- CJC-1295 with DAC: 1–2 mg SC, once or twice weekly
- Ipamorelin: 100–300 mcg SC, 1–3 times daily, often timed to fasting or pre-sleep (the natural GH surge occurs during slow-wave sleep)
These doses reflect the prescribing conventions from the 503A pharmacy era rather than Phase I dose-finding data for this specific combination. There is no published optimal dosing study for the stack. The timing rationale for pre-sleep Ipamorelin injection is to amplify the natural GH pulse that accompanies slow-wave sleep onset — exploiting the physiological rhythm rather than working against it. The sleep dimension of this combination is covered in spokes 6.15 (CJC-1295 and sleep quality) and 6.20 (Ipamorelin and sleep).
The dosing guide for each component separately is covered in spoke 3.27 (CJC-1295 dosing) and spoke 3.26 (Ipamorelin dosing). Reconstitution specifics are covered in our BAC water reconstitution guide.
Safety: what the literature covers and what it doesn't
The safety profile of each component individually is reasonably well-characterized from their respective development programs. The combined safety profile is not specifically published for the CJC-1295 + Ipamorelin combination in a dedicated human safety trial.
Insulin resistance: Both compounds stimulate GH/IGF-1 and each contributes to GH's insulin-counter-regulatory effect. Combined use likely amplifies the insulin-resistance signal vs either alone — though by how much is unstudied.
Pituitary adaptation: Whether repeated long-term dual-receptor stimulation causes GHRH-R or GHS-R1a desensitization, somatotroph hypertrophy, or any lasting change to the hypothalamic-pituitary somatotroph axis is not published for this combination at research-market doses and cycles.
Cancer-promotion potential: GH and IGF-1 have well-established roles in cell proliferation and angiogenesis. Sustained GH/IGF-1 elevation is not without theoretical cancer-risk implications, particularly for pre-existing occult malignancies. This is a class-level risk for all GH-axis peptides; no specific signal has emerged from the compounding pharmacy era, but systematic safety surveillance was not conducted.
See our general peptide side effects overview and the individual side-effect spokes (Ipamorelin side effects, spoke 3.24) for component-level safety detail.